ArticleNeurology. Clinical practice2025
Understanding the Opportunities in Dual Therapy and Emergency Department Utilization in Migraine Care.
Article in Neurology. Clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Value-based payment (VBP) models require organizations to understand conditions that are contributing to spending and utilization above negotiated targets. Headache was a top 10 reason for an emergency department (ED) visit in 2022. The high utilization continued with more than 2,000 ED visits for migraine in 2023. Nearly all these visits resulted in same-day discharge home, suggesting these may be avoidable. A Payvider council was used to affect medical policy change, and dual therapy for migraine treatment (concurrent use of anti-calcitonin gene-related peptide medications and onabotulinumtoxinA) was approved for coverage in May 2023. This study provides insight into the effect on cost and ED utilization of the medical policy change enabling dual therapy treatment of migraine by comparing cost for pharmacy and ED utilization across monotherapy or dual therapy patient groups. Methods: Patients with a prescription for 1 (monotherapy) or both (dual therapy) medications of interest with an ED encounter for migraine were reviewed. Based on the medications prescribed, patients were classified as receiving monotherapy or dual therapy for the treatment of migraine. The rates of emergency department utilization, ED utilization costs, and pharmacy costs were compared between the groups. This analysis was extrapolated to the larger migraine population within the organization to understand the cost effect of changing migraine management to the organization. Results: Three hundred fifty-seven health plan members used the ED posttreatment between January 1, 2023, and December 31, 2023. A significant difference ( Discussion: Dual therapy for migraine had a positive effect on ED visit utilization in our sample while also having cost implications. Health care systems and neurology providers may benefit from this assessment when establishing migraine care, developing data structures, and planning for VBP models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.